×
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96

Experts endorse Moderna COVID-19 shots for kids ages 6 to 17

Thursday, June 23, 2022 | Mike Stobbe, AP Medical Writer


Doses of the Moderna COVID-19 vaccine wait to be administered during a vaccination clinic in Odessa, Texas, on Tuesday, Aug. 24, 2021. On Thursday, June 23, 2022, an expert panel is recommending Moderna's COVID-19 shots for kids ages 6 to 17, marking another step toward bringing a second brand of vaccine for kids in that age group. (Eli Hartman/Odessa American via AP, File)

NEW YORK (AP) — An expert panel backed a second COVID-19 vaccine option for kids ages 6 to 17 Thursday.

Advisers to the U.S. Centers for Disease Control and Prevention voted unanimously to recommend Moderna shots as an option for school-age kids and adolescents. This group has been able to get shots shots made by Pfizer since last year.

The panel’s recommendations usually are adopted by the CDC, and become the government’s guidance for U.S. doctors and their patients.

Last week, the Food and Drug Administration authorized the shots — full-strength doses for children ages 12 to 17 and half-strength for those 6 to 11. The doses are to be given about a month apart.

The FDA also authorized a third dose for kids with significantly weakened immune systems, to be given about a month after the second dose of the primary series. The CDC is expected to recommend the same thing.

Moderna officials have said they expect to later offer a booster to all kids ages 6 to 17.

How much demand there will be for the shots isn’t clear. Teens became eligible a year ago for Pfizer’s vaccine, which uses the same technology, and only 60% have gotten two doses. Shots for younger kids started in November; about 29% have been fully vaccinated, according to the CDC.

More than 600 COVID-19 deaths have been reported in kids ages 5 to 17 in the U.S. Health officials also have voiced concern about the increased risk of long-lasting health problems in children after infection, such as diabetes or problems with smell or taste.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.


7 Agricultural Technology Stocks to Buy as Commodity Prices Remain Volatile

Agriculture stocks have a place in every investor's portfolio. The fact is that the byproduct of agriculture literally feeds the world. But for a variety of reasons, supply and/or demand can be disrupted. For example, the weather is often a concern. Farmers are always subject to periods of drought or flooding.

 But the past few years have shown how this sector is not immune from geopolitical concerns. The Covid-19 pandemic affected supply chains on top of seeing demand destruction in key markets. And this year, the world is seeing how interconnected we've become. Russia's war on Ukraine is shutting in a large percentage of the world's wheat supply.

However, with commodity prices soaring in several categories, investors have an opportunity in agriculture technology stocks. These companies run the gamut from companies that provide equipment to those that provide fertilizer, pesticides, and other products and services.

To help investors determine if this opportunity is right for them, we've created this special presentation. We assess the long-term opportunity for seven agricultural technology stocks.



View the "7 Agricultural Technology Stocks to Buy as Commodity Prices Remain Volatile".

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:


Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastIs The Market Near a Bottom, Does it Matter?

Today’s interview is a little different, in that you get a LOT of market perspective from someone who’s been analyzing stocks from the ground up, for more than three decades. In this conversation, Kate chats with Nancy Zambell, the chief analyst for the Cabot Money Club Letter - and Nancy has a really deep and varied background in the financial industry - as she mentions in this interview, she’s been a banker, real estate professional, and a stock market analyst.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.